Polypharmacology: challenges and opportunities in drug discovery.
暂无分享,去创建一个
[1] M. Kuhar,et al. The binding of vinblastine to tubulin and to particulate fractions of mammalian brain. , 1974, Cancer research.
[2] P. Verdouw,et al. Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. , 1985, Biochemical pharmacology.
[3] G. Muirhead,et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. , 1996, International journal of impotence research.
[4] W. Silverman. The schizophrenic career of a "monster drug". , 2002, Pediatrics.
[5] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[6] Jerry J Buccafusco,et al. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.
[7] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[8] B. Cronstein,et al. Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis , 2005, Pharmacological Reviews.
[9] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[10] Christopher M. Overall,et al. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.
[11] C. Chong,et al. New uses for old drugs , 2007, Nature.
[12] R. Krauss,et al. When good drugs go bad , 2007, Nature.
[13] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[14] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.
[15] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[16] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[17] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[18] K. Shokat,et al. Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.
[19] Tudor I. Oprea,et al. Quantifying the Relationships among Drug Classes , 2008, J. Chem. Inf. Model..
[20] Deok-Sun Lee,et al. A Mapping of Drug Space from the Viewpoint of Small Molecule Metabolism , 2009, PLoS Comput. Biol..
[21] David A. Fidock,et al. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria , 2009, Nature Reviews Microbiology.
[22] J. Mestres,et al. Conciliating binding efficiency and polypharmacology. , 2009, Trends in pharmacological sciences.
[23] Shuxing Zhang,et al. Mapping drug-target interaction networks , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[24] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[25] G. Degliesposti,et al. Binding Estimation after Refinement, a New Automated Procedure for the Refinement and Rescoring of Docked Ligands in Virtual Screening , 2009, Chemical biology & drug design.
[26] Giulio Rastelli,et al. Structure‐Based and in silico Design of Hsp90 Inhibitors , 2009, ChemMedChem.
[27] Mathias Wawer,et al. Navigating structure-activity landscapes. , 2009, Drug discovery today.
[28] Andrew J. S. Knox,et al. Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin. , 2009, Journal of medicinal chemistry.
[29] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[30] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[31] Jeffrey A. Cohen,et al. Combination therapy in multiple sclerosis , 2010, The Lancet Neurology.
[32] Jürgen Bajorath,et al. Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs , 2010, J. Chem. Inf. Model..
[33] D. Altieri. Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer. , 2010, Future oncology.
[34] Michael J. Keiser,et al. Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. , 2010, Journal of medicinal chemistry.
[35] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[36] J. Wright,et al. Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy , 2010, Clinical Cancer Research.
[37] J. Bajorath,et al. Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.
[38] Pablo C. Echeverría,et al. An Interaction Network Predicted from Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone Machine , 2011, PloS one.
[39] S. Larson,et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. , 2011, Nature chemical biology.
[40] Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials. , 2011, Clinical lung cancer.
[41] Anne Mai Wassermann,et al. Design of Multitarget Activity Landscapes That Capture Hierarchical Activity Cliff Distributions , 2011, J. Chem. Inf. Model..
[42] Alison Stopeck,et al. HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab , 2011, Clinical Cancer Research.
[43] M. Rask-Andersen,et al. Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.
[44] Philip E. Bourne,et al. Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir , 2011, PLoS Comput. Biol..
[45] Irene Bolea,et al. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. , 2011, Journal of medicinal chemistry.
[46] Maurizio Recanatini,et al. The role of fragment-based and computational methods in polypharmacology. , 2012, Drug discovery today.
[47] Jin-jian Lu,et al. Multi-Target Drugs: The Trend of Drug Research and Development , 2012, PloS one.
[48] J. Roder,et al. Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice , 2012, Neuropharmacology.
[49] Maria F. Sassano,et al. Automated design of ligands to polypharmacological profiles , 2012, Nature.
[50] Xiangyi Lu,et al. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. , 2012, Biochemical pharmacology.
[51] J. Richard Morphy,et al. Designing multi-target drugs , 2012 .
[52] Wolfgang Guba,et al. Can we discover pharmacological promiscuity early in the drug discovery process? , 2012, Drug discovery today.
[53] Gergely Zahoránszky-Köhalmi,et al. Drug Effect Prediction by Polypharmacology-Based Interaction Profiling , 2012, J. Chem. Inf. Model..
[54] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[55] L. Meijer,et al. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. , 2012, Journal of medicinal chemistry.
[56] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[57] Brian K Shoichet,et al. Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.
[58] Kevan M. Shokat,et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.
[59] G. Rastelli,et al. αC helix displacement as a general approach for allosteric modulation of protein kinases. , 2013, Drug discovery today.
[60] José Marco-Contelles,et al. Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease , 2013, Medicinal research reviews.
[61] Jürgen Bajorath,et al. High-resolution view of compound promiscuity , 2013, F1000Research.
[62] J. Roder,et al. Dual inhibitor of PDE7 and GSK-3 – VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice , 2013, Neuropharmacology.
[63] P. Bork,et al. Systematic identification of proteins that elicit drug side effects , 2013, Molecular systems biology.
[64] Irina G. Tikhonova,et al. Addressing Selective Polypharmacology of Antipsychotic Drugs Targeting the Bioaminergic Receptors through Receptor Dynamic Conformational Ensembles , 2013, J. Chem. Inf. Model..
[65] Jürgen Bajorath,et al. Systematic Identification of Scaffolds Representing Compounds Active against Individual Targets and Single or Multiple Target Families , 2013, J. Chem. Inf. Model..
[66] Emidio Camaioni,et al. PARP inhibitors: polypharmacology versus selective inhibition , 2013, The FEBS journal.
[67] Jürgen Bajorath,et al. Activity profile relationships between structurally similar promiscuous compounds. , 2013, European journal of medicinal chemistry.
[68] C. Ballard,et al. Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease , 2013, Pharmaceuticals.
[69] J. Mestres,et al. On the origins of drug polypharmacology , 2013 .
[70] R. Geney,et al. Type II kinase inhibitors: an opportunity in cancer for rational design. , 2013, Anti-cancer agents in medicinal chemistry.
[71] J. Bajorath,et al. Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.
[72] Jürgen Bajorath,et al. Promiscuity profiles of bioactive compounds: potency range and difference distributions and the relation to target numbers and families , 2013 .
[73] Mårten Fryknäs,et al. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer , 2013, Journal of Cancer Research and Clinical Oncology.
[74] Shuxing Zhang,et al. Polypharmacology: drug discovery for the future , 2013, Expert review of clinical pharmacology.
[75] G. Fontanini,et al. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. , 2013, The Journal of clinical endocrinology and metabolism.
[76] R. McKenna,et al. Insights towards sulfonamide drug specificity in α-carbonic anhydrases. , 2013, Bioorganic & medicinal chemistry.
[77] Giulio Rastelli. Emerging Topics in Structure-Based Virtual Screening , 2013, Pharmaceutical Research.
[78] L. Rubinstein,et al. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995–2011 , 2013, Melanoma research.
[79] Yuhong Du,et al. Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models. , 2013, Biochemical pharmacology.
[80] P. Sadler,et al. Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis , 2013, ACS chemical biology.
[81] Ruben Abagyan,et al. The GPCR Network: a large-scale collaboration to determine human GPCR structure and function , 2012, Nature Reviews Drug Discovery.
[82] J. Peters. Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.
[83] Giulio Rastelli,et al. Enrichment Factor Analyses on G-Protein Coupled Receptors with Known Crystal Structure , 2013, J. Chem. Inf. Model..
[84] Jürgen Bajorath,et al. New frontiers in kinases: second generation inhibitors. , 2014, Journal of medicinal chemistry.
[85] Petra Schneider,et al. Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus , 2014, Proceedings of the National Academy of Sciences.
[86] N. Curtin. PARP inhibitors for anticancer therapy. , 2014, Biochemical Society transactions.